The topline Phase 3 results from Eli Lilly ACHIEVE-1 study, evaluating the safety and efficacy of orforglipron compared to placebo in...

Spend an engaging hour with Researcher 2 Researcher   and Bariatric News   as we explore a range of topics in Bariatric and Metabolic...

A study led by researchers in the University of Florida College of Pharmacy has found that a pair of popular glucose-lowering drugs...

MetaVia has revealed positive results from the four-week multiple ascending dose (MAD) Part 2 of its Phase 1 clinical trial of DA-1726, a...

Skye Bioscience's novel CB1 antibody, nimacimab in combination with the dual GLP-1/GIP agonist, tripeptide, resulted in greater than 30%...

Investigators from Mass General Brigham who examined claims data from nearly two million people between 2021 and 2023, have reported a...

Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...

Researchers from the UK have designed a prospective, multi-centre, audit of bariatric surgical emergency (BSE) activity in all UK...

Johnson & Johnson MedTech has completed the first cases in the clinical trial for the OTTAVA Robotic Surgical System, the first clinical...

Virginia Tech neuroscientists at Fralin Biomedical Research Institute are part of a cross-disciplinary team that will explore how obesity...

Soleno Therapeutics has launched VYKAT XR (diazoxide choline) extended-release tablets, the company’s treatment for hyperphagia in...

Pfizer has decided to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist,...